HC
AERI

Henshaw Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Henshaw Capital’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,645
Closed -$347K – 336
2017
Q1 		$347K Hold
7,645
– – 0.04% 194
2016
Q4 		$289K Hold
7,645
– – 0.03% 211
2016
Q3 		$289K Buy
+7,645
New +$169K 0.04% 208

Other funds holding AERI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Henshaw Capital's AERI Position: Q2 2017 in Review

Henshaw Capital sold out of Aerie Pharmaceuticals (AERI) in Q2 2017, closing a stake of 7,645 shares — an estimated $347K sold.

Henshaw Capital first reported a position in AERI in Q3 2016 and held it in 3 quarters. The position peaked at $347K in Q1 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q2 2017.

  • Henshaw Capital reported no remaining Aerie Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Henshaw Capital sold 7,645 Aerie Pharmaceuticals shares in Q2 2017, an estimated $347K.
  • Henshaw Capital first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Henshaw Capital's Aerie Pharmaceuticals position peaked at $347K in Q1 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2017.

Based on Henshaw Capital's 13F filing for Q2 2017, filed 28 May 2026.